
Codiak BioSciences CDAK
Codiak BioSciences Gross Profit | CDAK
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Codiak BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.92 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.92 K | 2.92 K | 2.92 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Precision BioSciences
DTIL
|
24.3 M | $ 6.31 | 0.16 % | $ 80.9 M | ||
|
Dyadic International
DYAI
|
177 K | $ 0.45 | 0.31 % | $ 16.3 M | ||
|
Editas Medicine
EDIT
|
1.63 M | $ 2.79 | 6.49 % | $ 248 M | ||
|
Edesa Biotech
EDSA
|
311 K | $ 3.91 | 1.3 % | $ 22.2 M | ||
|
Enanta Pharmaceuticals
ENTA
|
41.9 M | $ 12.6 | 0.93 % | $ 269 K | ||
|
Entera Bio Ltd.
ENTX
|
9 K | $ 2.62 | 0.69 % | $ 121 M | ||
|
Eton Pharmaceuticals
ETON
|
42.7 M | $ 55.62 | 0.47 % | $ 1.5 B | ||
|
Evogene Ltd.
EVGN
|
-241 K | $ 0.4 | 3.54 % | $ 3.15 M | ||
|
Exelixis
EXEL
|
935 M | $ 58.85 | 0.79 % | $ 16 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
28.6 M | $ 3.15 | 0.62 % | $ 231 K | ||
|
Fate Therapeutics
FATE
|
2.43 M | $ 2.43 | 4.74 % | $ 289 M | ||
|
Fortress Biotech
FBIO
|
31 M | $ 2.09 | 2.96 % | $ 58.3 M | ||
|
Fennec Pharmaceuticals
FENC
|
20 M | $ 10.62 | 4.12 % | $ 303 M | ||
|
Merus N.V.
MRUS
|
-17.7 M | - | - | $ 5.78 B | ||
|
Geron Corporation
GERN
|
2.44 M | $ 1.21 | 0.83 % | $ 807 M | ||
|
Gilead Sciences
GILD
|
17.8 B | $ 144.63 | 0.85 % | $ 180 B | ||
|
Genmab A/S
GMAB
|
-182 M | $ 38.48 | 10.73 % | $ 2.49 B | ||
|
GeoVax Labs
GOVX
|
883 K | $ 0.32 | 1.31 % | $ 307 K | ||
|
Grifols, S.A.
GRFS
|
2.79 B | $ 7.41 | 1.37 % | $ 5.04 B | ||
|
GlaxoSmithKline plc
GSK
|
23.6 B | $ 46.55 | 0.93 % | $ 189 B | ||
|
GT Biopharma
GTBP
|
27 K | $ 6.16 | 0.98 % | $ 34 M | ||
|
Halozyme Therapeutics
HALO
|
150 M | $ 108.31 | 2.73 % | $ 13 B | ||
|
Hutchison China MediTech Limited
HCM
|
39.5 M | $ 14.31 | 0.77 % | $ 12.3 B | ||
|
Harmony Biosciences Holdings
HRMY
|
670 M | $ 39.92 | 0.71 % | $ 2.3 B | ||
|
Heron Therapeutics
HRTX
|
114 M | $ 0.37 | 6.44 % | $ 61.7 M | ||
|
iBio
IBIO
|
2.17 M | $ 1.12 | 0.89 % | $ 117 M | ||
|
ImmuCell Corporation
ICCC
|
11.4 M | $ 9.75 | 1.56 % | $ 88 M | ||
|
InflaRx N.V.
IFRX
|
-7.24 M | $ 1.68 | 0.58 % | $ 113 M | ||
|
Immutep Limited
IMMP
|
1.87 M | $ 4.27 | 0.46 % | $ 6.22 B | ||
|
Immuron Limited
IMRN
|
4.77 M | $ 1.07 | 0.46 % | $ 247 M | ||
|
Innate Pharma S.A.
IPHA
|
23.8 M | $ 1.58 | 1.28 % | $ 142 M | ||
|
Incyte Corporation
INCY
|
2.04 B | $ 114.13 | 0.06 % | $ 22.3 B | ||
|
InMed Pharmaceuticals
INM
|
1.71 M | $ 1.33 | 0.01 % | $ 5.54 M | ||
|
INmune Bio
INMB
|
-10.9 K | $ 1.94 | 0.52 % | $ 48 M | ||
|
Inovio Pharmaceuticals
INO
|
40.6 M | $ 1.15 | 2.05 % | $ 53.9 M | ||
|
Insmed Incorporated
INSM
|
112 M | $ 103.83 | 2.33 % | $ 20.7 B | ||
|
Innoviva
INVA
|
308 M | $ 20.64 | 0.68 % | $ 1.39 B |